Mary Beth DeYoung

Medicine · Health Sciences

17h-index1.6kcitations27works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(12), Diabetes Management and Research(12), Protease and Inhibitor Mechanisms(6), RNA and protein synthesis mechanisms(4), Cell Adhesion Molecules Research(4)

Publications27 total

Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals
Cardiovascular Diabetology·2013· 23 citedOpen Access
Optimizing the Clinical Use of the GLP-1 Receptor Agonist Exenatide Once Weekly
Diabetes Spectrum·2013· 1 cited
<scp>GLP</scp> ‐1 receptor activated insulin secretion from pancreatic β‐cells: mechanism and glucose dependence
Diabetes Obesity and Metabolism·2012· 355 citedOpen Access
Once-Weekly Glucose-Lowering Therapy for Type 2 Diabetes
Clinical Diabetes·2012· 1 citedOpen Access
Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
Clinical Therapeutics·2012· 249 cited
Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States
Journal of Medical Economics·2012· 23 cited
The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review
Diabetes Obesity and Metabolism·2011· 21 citedOpen Access
PDB11 Glycemic Outcomes Among Patients Receiving Exenatide BID or Liraglutide for Type 2 Diabetes in Clinical Practice: A Retrospective Analysis of the GE Centricity EMR Data
Value in Health·2011
PDB10 Achieving Target Goals in Patients with T2DM Treated with Exenatide Once Weekly or Insulin Glargine: A Retrospective Analysis of the Number-Needed-To-Treat
Value in Health·2011· 1 cited
Clinical Implications of Exenatide as a Twice-Daily or Once-Weekly Therapy for Type 2 Diabetes
Postgraduate Medicine·2011· 28 cited
Encapsulation of Exenatide in Poly-( <scp>d,l</scp> -Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes
Diabetes Technology & Therapeutics·2011· 234 cited
Dose Accuracy and Injection Force of Disposable Pens Delivering Pramlintide for the Treatment of Diabetes
Journal of Diabetes Science and Technology·2010· 4 citedOpen Access
Prophylactic use of anti‐emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open‐label, parallel‐group, single‐dose study in healthy subjects
Diabetic Medicine·2010· 33 citedOpen Access
Macrophage-Targeted Overexpression of Urokinase Causes Accelerated Atherosclerosis, Coronary Artery Occlusions, and Premature Death
Circulation·2004· 87 cited
Determination of Catalytic Parameters for Hairpin Ribozymes
Humana Press eBooks·2003· 11 cited
Mutagenesis and Modeling of the Hairpin Ribozyme Family
Humana Press eBooks·2003· 5 cited
Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth
Proceedings of the National Academy of Sciences·2002· 55 citedOpen Access
Plasminogen Activator Inhibitor Type 1 Increases Neointima Formation in Balloon-Injured Rat Carotid Arteries
Circulation·2001· 80 cited
Expression of Fas Ligand in Arteries of Hypercholesterolemic Rabbits Accelerates Atherosclerotic Lesion Formation
Arteriosclerosis Thrombosis and Vascular Biology·2000· 76 citedOpen Access
Optimizing Vascular Gene Transfer of Plasminogen Activator Inhibitor 1
Human Gene Therapy·1999· 18 cited
page 1 of 2Next →

Frequent Co-authors

David A. Dichek(7), Andrew Siwkowski(4), Arnold Hampel(4), Jennie H. Best(4), A. Meloni(2), Vanita R. Aroda(2), Jenny Han(2), Clifford Tom(2), Shan Wen(2), Robert Driscoll(2), Ruth Linnemann(2), Susan Μ. LaRue(2), Steve Chen(2), Amy Blickensderfer(2), Catherine Lowe(1), David G. Parkes(1), Robert R. Henry(1), Wenying Huang(1), Tamara Darsow(1), Byron J. Hoogwerf(1)